SCHEMBL3093295

SCHEMBL3093295

Cc1ccc(Cc2[c]n(C)c3ccccc23)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX4 Q99571 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.38
TP53 P04637 2/20 0.38
LMNA P02545 2/20 0.38
HTT P42858 2/20 0.38
MEN1 O00255 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38
RECQL P46063 1/20 0.37
MAPK10 P53779 1/20 0.37
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
HPGD P15428 1/20 0.36
DNM1 Q05193 3/20 0.36
HTR6 P50406 1/20 0.36
ADRA1A P35348 1/20 0.36
HRH1 P35367 1/20 0.36
ADRA1B P35368 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3083896 0.87 PTPN5 (0.36) TP53LMNAMEN1KMT2AKDM4E
SCHEMBL3073685 0.83 MAPT (0.36) SMN1; SMN2TP53LMNAMEN1MAPT
SCHEMBL3091116 0.83 LTA4H (0.49) P2RX4SMN1; SMN2TP53LMNAHTT
SCHEMBL3090755 0.83 SLC6A4 (0.41) SMN1; SMN2MEN1MAPTKMT2AKDM4E
SCHEMBL2075131 0.69 GPR3 (0.46) HTTMAPTKDM4EALDH1A1HPGD
SCHEMBL3093301 0.69 GPR84 (0.71) TP53LMNAHTTMEN1KMT2A
SCHEMBL21987841 0.68 KDM4E (0.53) P2RX4SMN1; SMN2TP53LMNAHTT
SCHEMBL31092716 0.68 KDM4E (0.59) P2RX4SMN1; SMN2TP53HTTMEN1
SCHEMBL29249817 0.68 KDM4E (0.59) P2RX4SMN1; SMN2TP53HTTMEN1
SCHEMBL17150144 0.67 P2RX4 (0.57) P2RX4RECQLMAPK10KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207134-B2 Fused ring spiroketal derivative and use thereof as anti-diabetic drug CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-06-26 US disclosed
US-20100234609-A1 FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-09-16 US disclosed
EP-2048152-A1 FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS DRUG FOR TREATING DIABETES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-04-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234609-A1 FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG REN, WNK1, GCKR P2RX4 1442/4885SMN1; SMN2 3852/4885TP53 4276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.